Rein Therapeutics is a clinical-stage biopharmaceutical company advancing a novel pipeline of first-in-class therapies to address significant unmet medical needs in orphan pulmonary and fibrosis indications. Rein's lead product candidate, LTI-03, is a novel, synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. LTI-03 is anticipated to initiate a Phase 2 clinical trial in the first half of 2025 for the treatment of idiopathic pulmonary fibrosis. Rein’s second product candidate, LTI-01, is a proenzyme that has completed Phase 1b and Phase 2a clinical trials for the treatment of loculated pleural effusions. LTI-01 has received Orphan Drug Designation in the U.S. and E.U. and Fast Track Designation in the U.S.
For more information, please visit www.reintx.com or follow us on Twitter at @Rein_Tx.
Company Details
- Employees
- 17
- Founded
- -
- Address
- 12407 N Mo Pac Expy,
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://reintx.com
- HQ
- Austin, Texas
Rein Therapeutics Questions
Rein Therapeutics's website is http://reintx.com
Rein Therapeutics's LinkedIn profile is https://www.linkedin.com/company/rein-therapeutics
Rein Therapeutics has
17 employees.
View email and phone details for 17
employees at Rein Therapeutics.
Rein Therapeutics's industry is
Biotechnology Research
Rein Therapeutics's top competitors are
Lung Therapeutics,
Sarepta Therapeutics,
Orna Therapeutics,
Tessera Therapeutics,
Qureight,
C4 Therapeutics, Inc.,
Avalyn Pharma,
Respira Therapeutics, Inc.,
Javara,
Soleno Therapeutics, Inc..
Rein Therapeutics's categories are Biotechnology Research
Rein Therapeutics's founding year is 2025
